0 Item
My accountOur History
tebu-bio past & present
2017We are pleased to launch a new service for 3D cell culture spheroid production, recreating the 3D environment seen in the body, thus permitting complex in vitro cell / tissue interactions thus mimicking in vivo environments.
tebu-bio again this year presented a poster at the AACR meeting in Washington, DC (USA). Nadia Normand Ph.D, Business Development Manager at tebu-bio, presented our abstract produced in collaboration with the CNRS (France), Anaxomics (Spain) and the Institute of Immunology and Experimental Therapy (Poland) :
"miRNome analyses reveal that activity of CAF expressed podoplanin in the tumour microenvironment is modulated by exosome miRNAs involved in PTEN/PI3K/AKT/mTOR signalling"
tebu-bio's CIR accreditation is again renewed for a further three years (2017, 2018 & 2019), enabling private French companies to benefit from tax refunds on their expenses for R&D performed by tebu-bio's own European laboratories based near Paris. We initially obtained this accreditation in 2008, which has subsequently been renewed each time.
2016
tebu-bio is pleased to announce their distribution agreement with Dojindo EU GmbH, under which tebu-bio becomes their European distributor as from June 1st, 2016. Dojindo is a renowned chemical reagent manufacture for chelating agents, analytical chemistry, diagnostic research, molecular biology, cell biology, oxidative stress research.
tebu-bio enters an agreement to provide European researchers with access to Time Bioscience's rapidly growing portfolio of drug discovery platforms, consisting of high quality proteins involved in the Wnt/catenin pathway and reporter cell lines designed to monitor the activity of β-catenin-based Wnt signal transduction pathway.
2015
Nadia Normand, R&D manager at tebu-bio's laboratories, was pleased to present two posters at the AACR meeting in Philadelphia in April:- Comparison of different highly sensitive miRNA array platforms for the investigation of circulating cell-free microRNAs in blood
- Cytokine profiling of drug-disrupted tumor cell/fibroblast crosstalk provides insights to understand the protective role of the stroma in collaboration with the Institut Català d'Oncologia.
2014
As a European-based services provider in genomics, proteomics and cell-based assays, tebu-bio enlarges their service portfolio by offering Toray's 3D-Gene® microRNA and mRNA profiling technology to European researchers (see press release).
tebu-bio is pleased to announce their distribution agreement with Stemgent-Asterand, under which tebu-bio becomes their exclusive European distributor as from July 15, 2014.tebu-bio's CIR accreditation is again renewed for a further three years (2014, 2015 & 2016), enabling private French companies to benefit from tax refunds on their expenses for R&D performed by tebu-bio's own European laboratories based near Paris. We initially obtained this accreditation in 2008, later renewed for the first time in 2011.
tebu-bio launches a series of new e-Newsletters and a blog named "Being bio-reactive", aimed at informing and sharing news in Life Sciences and Biotechnologies.
tebu-bio participates in the "Experimental and Molecular Therapeutics" poster sessions at the AACR 2014 (San Diego, USA) to present the recent data in Drug Discovery obtained with the SilenciX® KD cellular model applied to synthetic lethality in oxygen controlled (hypoxic) conditions similar to tumor physioxia.
2013
tebu-bio is a partner of the Glycoskin 1 project, certified by the Cosmetic Valley competitive cluster, which has been selected among the call for proposals (AAP) of the FUI 16. tebu-bio brings to the project their expertise in the screening of molecules in cellular models and in multiplex studies to this project.
tebu-bio selects StemCultures' Stem Beads FGF2 (but also Activin-A and EGF), a revolutionary growth factor supplement offering a far more efficient way to grow FGF2 dependent stem cells and iPS cells by enabling feeding only bi-weekly.
To cover researchers' needs for high quality & high purity fluorescent & luminescent dyes and assays, our experts choose Marker Gene Technologies, expanding tebu-bio's existing offer in nucleic acid labelling, cell-based assays, live imaging and molecular biology by 300+ references.
A variety of new, innovative brands for cell culture are introduced, among which GlobalStem and Celartia. tebu-bio also enters into partnerships with Eurogentec (for their research antibodies and molecular biology solutions), and Detroit R&D (antibodies, ELISA kits & antibody arrays).
The French Government renews tebu-bio's authorisation to import, export and store primary cells, valid for all our customers throughout Europe (licence IE-2013-677, valid for a period of 5 years).
tebu-bio and tebu-bio Laboratories merge to form a single company, to more efficiently provide reagents & services to researchers across Europe.
2012
.png){kind=logo}
tebu-bio has been designated one of the winners the PM'up award in the Health/Life Sciences sector, which is attributed by the "Region Ile de France" (regional government).
This award is is given to companies selected by a jury, in recognition of their innovation, capacity to create value and employment, development of international business and efforts towards sustainable development.
Winners receive guidance and financial support for three years, enabling them to drive growth and access funds for development.
tebu-bio Laboratories launch a new Human Recombinant protein expression platform in HEK293 cells, and also introduce Endocrine Disruptor Screening services.
tebu-bio Laboratories become RayBiotech's Certified European services provider.
tebu-bio's broad and varied Antibody offer is further enhanced with guaranteed antibodies validated for popular applications. We proudly present our new antibody mascot! Among the new brands: Quansys Biosciences, Sunred Biological Technology, EnoGene Biotech, Assay Biotechnology, MUbio, Biosensis, Osenses, Full Moon Biosystems...
2011
Our presence in Portugal is further strengthened with the opening of our new offices near Lisbon.
tebu-bio Laboratories receive official renewal of their CIR (Crédit d'Impôt sur la Recherche) accreditation.
tebu-bio Laboratories receive official renewal of their CIR (Crédit d'Impôt sur la Recherche) accreditation.
2010
Merger of tebu-bio's and tebu-bio Laboratories quality management systems into a single ISO certification.
2009
Optimisation of our supply chain through ERP developments, for improved stock handling and faster delivery. Our local presence in Portugal is further strengthened with the opening of a new subsidiary.
2008
Implementation of a new more powerful ERP for better customer service.
2007
Launch of our own stable silenced cell lines, SilenciX, in collaboration with the CEA. Our protein production platform is optimised, integrating new CHO protein expression technologies.
2006
tebu-bio laboratories are recognised by the French Government as a Young Innovative Company in the Biotechnology field.
2005
Opening of tebu-bio in Spain & Portugal.
2004
A second extension is added to accommodate the laboratory, which is now also ISO certified. 750 square meters are dedicated to various activities of the laboratory.
tebu-bio APS is opened in Denmark, covering all Nordic territories.
tebu-bio APS is opened in Denmark, covering all Nordic territories.
2003
Celebrating 50 years of the company name, a large gathering of staff from all offices takes place at Le-Perray-en-Yvelines.
A new unified name is chosen for the group, tebu-bio. SPB is renamed to tebu-bio laboratories.
A shadow is added to the logo.
A new unified name is chosen for the group, tebu-bio. SPB is renamed to tebu-bio laboratories.
A shadow is added to the logo.
2001
ISO 9001-2000 accreditation is obtained for tebu-bio.
2000
La Société Perrotine de Biotechnologies (SPB) is created, with laboratory facilities offering services to private and academic companies.
Premises at Le Perray are extended to include larger offices for technical sales staff, IT, accounting…
The whole of the original building is dedicated to a new Logistics department.
Premises at Le Perray are extended to include larger offices for technical sales staff, IT, accounting…
The whole of the original building is dedicated to a new Logistics department.
1998
TOTAM Biologicals is opened in the UK, and Trimital SRL is acquired in Italy. With the number of companies growing, the "drop" becomes our logo.
1992 & 1995
Opening of SanverTECH nv in Belgium and subsequently a second company with the same name in the Netherlands; TEBU GmbH is opened in Germany.
1989 & 1991
The number of companies represented has grown to over 20, distribution of the SERVA products is ended. For the first time, the entire turn-over of the company is generated by laboratory reagents.
1987
Extension of the building with a larger warehouse and shipping department.
1985
A new logo is introduced. The droplet was designed to reflect our activities including fluids and the horizontal line illustrates the cap of a bottle.
1980
TEBU moves to new premises at Le-Perray-en-Yvelines, and a new logo with the company name is designed.
1979
TEBU France is acquired by the van Dijk family. The 'laboratory division' is staffed by 2 people and represents 1/3 of total sales. The new owners aim to develop this activity.
1974
Larger facilities are required as laboratory related activities are growing: TEBU moves to Versailles.
1968
C.Ch. van Dijk is appointed General Manager of TEBU France in Paris. Besides selling the products manufactured in the Netherlands, trading in industrial chemicals becomes a new activity.
1953
TEBU France is established as a subsidiary of the Teer Bedrijf Uithoorn, a Dutch tar processing company.
Based in Paris, the new company promotes and sells products manufactured by the Dutch plant.
Based in Paris, the new company promotes and sells products manufactured by the Dutch plant.
